A novel cancer vaccine produced with cell reprogramming
| Project/Area Number |
24650628
|
|---|
| Research Category |
Grant-in-Aid for Challenging Exploratory Research
|
| Allocation Type | Single-year Grants |
|---|
| Research Field |
Tumor immunology
|
|---|
| Research Institution | Hokkaido University |
|---|
Principal Investigator |
SEINO kenichiro 北海道大学, 遺伝子病制御研究所, 教授 (20312845)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
WADA Haruka 北海道大学, 遺伝子病制御研究所, 講師 (70392181)
|
|---|
| Project Period (FY) |
2012-04-01 – 2014-03-31
|
| Project Status |
Completed (Fiscal Year 2013)
|
| Budget Amount *help |
¥3,900,000 (Direct Cost: ¥3,000,000、Indirect Cost: ¥900,000)
Fiscal Year 2013: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
Fiscal Year 2012: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
|---|
| Keywords | がん幹細胞 |
|---|
| Research Abstract |
Recently, it has been suggested that there is a stem cell fraction in cancer. To establish an efficient therapy against cancer, it is reasonable to target the cancer stem cells. In this study, we have examined immunological features of cancer stem cells. We have obtained mouse glioma stem and non-stem cells. When examined there cell surface phenotype, we found that MHC class I was expressed higher in the stem cells than in non-stem cells. MHC class I is known as a suppressor molecule for NK cells. Then, we performed NK cell mediated cytotoxicity assay. In this sassy, the cancer stem fraction were killed more than no stem fraction. Therefore, it was suggested that cancer stem cells suppress NK cell function and then obtained the tumor-initiating capacity.
|
Report
(3 results)
Research Products
(18 results)
